|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...6364656667686970717273...110111» |
- Trial primary completion date: Gametes Transfer vs. Embryo Transfer for Women Undergoing Assisted Reproductive Techniques: a Randomized Controlled Trial (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=40, Terminated, Sponsor: University of Sao Paulo
Trial primary completion date: May 2015 --> Feb 2014
- Preclinical, Trial primary completion date: Optimizing the Temperature for Embryo Culture in In Vitro Fertilization (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=100, Active, not recruiting, Sponsor: Reproductive Medicine Associates of New Jersey
Trial primary completion date: May 2015 --> Feb 2014 Trial primary completion date: Jan 2013 --> Jan 2015
- || Trial primary completion date: Single Embryo Transfer of a Euploid Embryo Versus Double Embryo Transfer (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: Reproductive Medicine Associates of New Jersey
Trial primary completion date: Jan 2013 --> Jan 2015 Trial primary completion date: Jul 2013 --> Jul 2014
- Trial termination: Gametes Transfer vs. Embryo Transfer for Women Undergoing Assisted Reproductive Techniques: a Randomized Controlled Trial (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=40, Terminated, Sponsor: University of Sao Paulo
Trial primary completion date: Jul 2013 --> Jul 2014 Recruiting --> Terminated; Low pregnancy rates in both groups
- Trial termination: DHEAFert: Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility (clinicaltrials.gov) - Jul 1, 2014
P2/3, N=35, Terminated, Sponsor: Center for Human Reproduction
Recruiting --> Terminated; Low pregnancy rates in both groups Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects
- Enrollment change, Trial termination, Trial primary completion date: Gametes Transfer vs. Embryo Transfer for Women Undergoing Assisted Reproductive Techniques: a Randomized Controlled Trial (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=40, Terminated, Sponsor: University of Sao Paulo
Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects N=100 --> 40 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Feb 2014; Low pregnancy rates in both groups
- Enrollment change, Trial termination: DHEAFert: Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility (clinicaltrials.gov) - Jul 1, 2014
P2/3, N=35, Terminated, Sponsor: Center for Human Reproduction
N=100 --> 40 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Feb 2014; Low pregnancy rates in both groups N=220 --> 35 | Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects
- |||| Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment open, Trial primary completion date: Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - Jun 29, 2014
P2, N=350, Recruiting, Sponsor: Prima BioMed Ltd
N=220 --> 35 | Recruiting --> Terminated; Failure to recruit designed nuimebrt of subjects Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Jul 2015
- Trial primary completion date: DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women (clinicaltrials.gov) - Jun 27, 2014
P4, N=99, Completed, Sponsor: Tulane University Health Sciences Center
Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Jul 2015 Trial primary completion date: Dec 2016 --> Apr 2014
- Trial primary completion date: Ovarian Reserve After Ovarian Hemostasis by Floseal Matrix (clinicaltrials.gov) - Jun 27, 2014
P3, N=100, Completed, Sponsor: CHA University
Trial primary completion date: Dec 2016 --> Apr 2014 Trial primary completion date: May 2014 --> Oct 2013
- Trial primary completion date: Prevalence of Polycystic Ovary Syndrome (PCOS) in Obese Premenopausal Women (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=500, Recruiting, Sponsor: Göteborg University
Trial primary completion date: May 2014 --> Oct 2013 Trial primary completion date: Dec 2013 --> Sep 2014
- Trial suspension: Trichomonas Vaginalis Repeat Infections Among HIV Negative Women (clinicaltrials.gov) - Jun 27, 2014
P3, N=1664, Suspended, Sponsor: Tulane University Health Sciences Center
Trial primary completion date: Dec 2013 --> Sep 2014 Recruiting --> Suspended
- Enrollment change: DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women (clinicaltrials.gov) - Jun 27, 2014
P4, N=99, Completed, Sponsor: Tulane University Health Sciences Center
Recruiting --> Suspended N=30 --> 99
- Enrollment change: Trichomonas Vaginalis Repeat Infections Among HIV Negative Women (clinicaltrials.gov) - Jun 27, 2014
P3, N=1664, Suspended, Sponsor: Tulane University Health Sciences Center
N=30 --> 99 N=2883 --> 1664
- Phase classification, Enrollment change, Trial suspension: Trichomonas Vaginalis Repeat Infections Among HIV Negative Women (clinicaltrials.gov) - Jun 27, 2014
P3, N=1664, Suspended, Sponsor: Tulane University Health Sciences Center
N=2883 --> 1664 Phase classification: P4 --> P3 | N=2883 --> 1664 | Recruiting --> Suspended
- New P3 trial: Effectiveness of Homeopathic Treatment in Female Infertility (clinicaltrials.gov) - Jun 27, 2014
P3, N=40, Recruiting, Sponsor: Fr Muller Homoeopathic Medical College
- Biomarker, Trial completion: Individualization of Ovarian Stimulation Using AMH Maximizes the Benefits and Minimizes Complications and Risks (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=250, Completed, Sponsor: ANDROFERT - Clinica de Andrologia e Reproducao Humana
Phase classification: P4 --> P3 | N=2883 --> 1664 | Recruiting --> Suspended Recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women (clinicaltrials.gov) - Jun 27, 2014
P4, N=99, Completed, Sponsor: Tulane University Health Sciences Center
Recruiting --> Completed Recruiting --> Completed | N=30 --> 99 | Trial primary completion date: Dec 2016 --> Apr 2014
- | Trial completion, Trial primary completion date: Ovarian Reserve After Ovarian Hemostasis by Floseal Matrix (clinicaltrials.gov) - Jun 27, 2014
P3, N=100, Completed, Sponsor: CHA University
Recruiting --> Completed | N=30 --> 99 | Trial primary completion date: Dec 2016 --> Apr 2014 Recruiting --> Completed | Trial primary completion date: May 2014 --> Oct 2013
- || volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial primary completion date, Monotherapy: BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer (clinicaltrials.gov) - Jun 27, 2014
P2, N=110, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | Trial primary completion date: May 2014 --> Oct 2013 Trial primary completion date: Oct 2011 --> Jun 2014
- || Enrollment change: CARE: Chemo- and Radiotherapy in Epithelial Vulvar Cancer (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=1618, Completed, Sponsor: AGO Study Group
Trial primary completion date: Oct 2011 --> Jun 2014 N=1000 --> 1618
- ||| Trial completion, Enrollment change: CARE: Chemo- and Radiotherapy in Epithelial Vulvar Cancer (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=1618, Completed, Sponsor: AGO Study Group
N=1000 --> 1618 Recruiting --> Completed | N=1000 --> 1618
- |||| volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial completion, Trial primary completion date, Monotherapy: BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer (clinicaltrials.gov) - Jun 27, 2014
P2, N=110, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | N=1000 --> 1618 Active, not recruiting --> Completed | Trial primary completion date: Oct 2011 --> Jun 2014
- progesterone / Generic mfg.
Trial primary completion date: Intrauterine Insemination and Luteal Fase Support (clinicaltrials.gov) - Jun 26, 2014
P4, N=198, Enrolling by invitation, Sponsor: Universitaire Ziekenhuizen Leuven
Active, not recruiting --> Completed | Trial primary completion date: Oct 2011 --> Jun 2014 Trial primary completion date: May 2014 --> May 2015
- Trial primary completion date: Comparison of DuoFertility, LadyComp/BabyComp and Clearblue Monitors (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=30, Completed, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Trial primary completion date: May 2014 --> May 2015 Trial primary completion date: Jul 2011 --> May 2014
- | Trial completion, Trial primary completion date: Comparison of DuoFertility, LadyComp/BabyComp and Clearblue Monitors (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=30, Completed, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Trial primary completion date: Jul 2011 --> May 2014 Active, not recruiting --> Completed | Trial primary completion date: Jul 2011 --> May 2014
- afuresertib (LAE002) / Laekna Therap
Trial primary completion date, Combination therapy: Dose-finding Study in Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Jun 26, 2014
P1/2, N=43, Recruiting, Sponsor: Accenture
Active, not recruiting --> Completed | Trial primary completion date: Jul 2011 --> May 2014 Trial primary completion date: Aug 2014 --> Feb 2016
- Vectibix (panitumumab) / Amgen
Trial primary completion date: PanGem: Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (clinicaltrials.gov) - Jun 26, 2014
P2, N=7, Terminated, Sponsor: Women and Infants Hospital of Rhode Island
Trial primary completion date: Aug 2014 --> Feb 2016 Trial primary completion date: Feb 2013 --> Oct 2013
- veliparib (ABT-888) / AbbVie
Trial primary completion date, BRCA Biomarker, PARP Biomarker: Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy (clinicaltrials.gov) - Jun 26, 2014
P1, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2013 --> Oct 2013 Trial primary completion date: Jun 2014 --> Dec 2014
- Vectibix (panitumumab) / Amgen
Trial termination: PanGem: Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (clinicaltrials.gov) - Jun 26, 2014
P2, N=7, Terminated, Sponsor: Women and Infants Hospital of Rhode Island
Trial primary completion date: Jun 2014 --> Dec 2014 Recruiting --> Terminated; Newer technologies available; poor accrual to study.
- Vectibix (panitumumab) / Amgen
Enrollment change, Trial termination, Trial primary completion date: PanGem: Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (clinicaltrials.gov) - Jun 26, 2014
P2, N=7, Terminated, Sponsor: Women and Infants Hospital of Rhode Island
Recruiting --> Terminated; Newer technologies available; poor accrual to study. N=35 --> 7 | Recruiting --> Terminated | Trial primary completion date: Feb 2013 --> Oct 2013; Newer technologies available; poor accrual to study.
- Avastin (bevacizumab) / Roche
Trial completion, Surgery: Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer (clinicaltrials.gov) - Jun 26, 2014
P2, N=34, Completed, Sponsor: National Cancer Institute (NCI)
N=35 --> 7 | Recruiting --> Terminated | Trial primary completion date: Feb 2013 --> Oct 2013; Newer technologies available; poor accrual to study. Active, not recruiting --> Completed
- Trial primary completion date: ROBO-GYN: Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy (clinicaltrials.gov) - Jun 24, 2014
P3, N=374, Recruiting, Sponsor: Centre Oscar Lambret
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Jun 2016
- | topotecan / Generic mfg.
Trial completion: Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jun 24, 2014
P2, N=81, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Jun 2015 --> Jun 2016 Active, not recruiting --> Completed
- | carboplatin / Generic mfg., paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion: AGO-OVAR9: Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 24, 2014
P3, N=1742, Completed, Sponsor: AGO Study Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Preclinical, Trial primary completion date: Stress Management for Couples Undergoing In Vitro Fertilization (IVF) (clinicaltrials.gov) - Jun 22, 2014
P2, N=80, Recruiting, Sponsor: Amit Sood
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Oct 2014
- Trial completion: Salpingectomy Versus Aspiration of Hydrosalpingeal Fluid Prior to IVF-ET (clinicaltrials.gov) - Jun 22, 2014
P2, N=140, Completed, Sponsor: Aljazeera Hospital
Trial primary completion date: Jun 2014 --> Oct 2014 Recruiting --> Completed
- ||||| Avastin (bevacizumab) / Roche
Enrollment closed: A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer (clinicaltrials.gov) - Jun 22, 2014
P3, N=1043, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Recruiting --> Active, not recruiting
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial primary completion date: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (clinicaltrials.gov) - Jun 19, 2014
P2, N=9, Completed, Sponsor: Prima BioMed Ltd
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2013 --> Apr 2014
- medroxyprogesterone injection / Generic mfg.
Trial primary completion date, Adverse events: Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects (clinicaltrials.gov) - Jun 19, 2014
P3, N=45, Active, not recruiting, Sponsor: Nationwide Children's Hospital
Trial primary completion date: Dec 2013 --> Apr 2014 Trial primary completion date: Jul 2014 --> Oct 2014
- || Preclinical, Enrollment change: Chronic Endometritis in Patients With Recurrent Miscarriages or Repeated Implantation Failures in In-vitro Fertilization (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=100, Recruiting, Sponsor: OVO R & D
Trial primary completion date: Jul 2014 --> Oct 2014 N=60 --> 100
- ||| Enrollment open, Preclinical, Enrollment change: Chronic Endometritis in Patients With Recurrent Miscarriages or Repeated Implantation Failures in In-vitro Fertilization (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=100, Recruiting, Sponsor: OVO R & D
N=60 --> 100 Completed --> Recruiting | N=60 --> 100
- medroxyprogesterone injection / Generic mfg.
Enrollment closed, Trial primary completion date, Adverse events: Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects (clinicaltrials.gov) - Jun 19, 2014
P3, N=45, Active, not recruiting, Sponsor: Nationwide Children's Hospital
Completed --> Recruiting | N=60 --> 100 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Oct 2014
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial completion, Trial primary completion date: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (clinicaltrials.gov) - Jun 19, 2014
P2, N=9, Completed, Sponsor: Prima BioMed Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Oct 2014 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Apr 2014
- seribantumab (MM-121) / Elevation Oncology
Trial primary completion date, Combination therapy, Metastases: A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers (clinicaltrials.gov) - Jun 19, 2014
P1, N=24, Active, not recruiting, Sponsor: Merrimack Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Apr 2014 Trial primary completion date: Dec 2013 --> Jul 2014
- Recentin (cediranib) / AstraZeneca, RG4733 / Roche
Trial primary completion date, Metastases: Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 19, 2014
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2013 --> Jul 2014 Trial primary completion date: May 2014 --> Aug 2014
- || trebananib (AMG 386) / Amgen
Trial primary completion date, Combination therapy, Metastases: AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR (clinicaltrials.gov) - Jun 19, 2014
P1, N=103, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: May 2014 --> Aug 2014 Trial primary completion date: Jun 2014 --> Sep 2014
- Avastin (bevacizumab) / Roche
Trial primary completion date: Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma (clinicaltrials.gov) - Jun 19, 2014
P2, N=19, Terminated, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jun 2014 --> Sep 2014 Trial primary completion date: Jun 2011 --> Jan 2011
- Avastin (bevacizumab) / Roche
Trial termination: Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma (clinicaltrials.gov) - Jun 19, 2014
P2, N=19, Terminated, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jun 2011 --> Jan 2011 Active, not recruiting --> Terminated; THe study was terminated early due to a lack of accural
- || PF-06263507 / Pfizer
Enrollment change, Metastases: A Study Of PF-06263507 In Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 19, 2014
P1, N=105, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Terminated; THe study was terminated early due to a lack of accural N=75 --> 105